Triple Combination Therapy of Choroidal Neovascularization in Exudative Age-related Macular Degeneration - a Cost Effect and Efficient Therapeutic Treatment
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- BEST CORRECTED VISUAL ACUITY
研究概览
简要总结
We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and Photo-dynamic therapy) during the years of 2006 to 2010 at The Retina Center and compare those results with an additional group of approximately 200 patients also treated with triple combination therapy and 20 mg of daily oral zeaxanthin.
详细描述
Study parameters will include best corrected visual acuity, number of combination treatments, reduction of central foveal thickness by OCT measurement and development of exudative macular degeneration in the fellow eye. Follow up will include all patients with a minimum of two years. Retrospective review of patient charts in the office of The Retina Center.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •MUST HAVE AGE RELATED MACULAR DEGENERATION
排除标准
- 未提供
结局指标
主要结局
BEST CORRECTED VISUAL ACUITY
时间窗: REVIEW OF EXAMINATION SHEETS
次要结局
- DEVELOPMENT OF EXUDATIVE MACULAR DEGENERATION IN THE FELLOW EYE(REVIEW OF CHART)
- REDUCTION OF CENTRAL FOVEAL THICKNESS BY OCT MEASUREMENT(REVIEW OF CHART)
- NUMBER OF COMBINATION TREATMENTS(REVIEW OF CHART)